In the fight against cancer, immunotherapies represent the next frontier. However, they have only been effective in 20–30% of patients. Enter: a better mouse model that makes immunotherapies more translational. Read more from Aidan Synnott of Charles River in STAT.
Charles River Laboratories has announced an "end-to-end" service offering of CRISPR/Cas9 genome engineering technology, including custom in vivo and in vitro genome editing.
In the field of stem cell therapies, advances have spawned questions about the safety and use of these products. What guidance has been provided by the FDA? Shawna Jackman, PhD, principal research scientist at Charles River, discusses in GEN.
Biopharmaceuticals are continuing to expand their share of the new drug pipeline, as traditional monoclonal antibody and recombinant protein products are joined by biosimilars and more novel therapies like antibody-drug conjugates (ADCs), bi-specific antibodies and gene and cell therapies. However, the cost and technical challenges inherent in working with larger, more complex molecules continue to affect movement of these products through the pipeline.
Scientists have a deep understanding of the strengths and shortcomings of research models, which gives them insight when validating new compounds. This has ultimately helped lead the charge in developing more complex models for neuroscience research. Patrick Sweeney from Charles River discusses in GEN.
A 2013 study reported that only 43% of cell lines could be uniquely identified, indicating that cell line authentication is crucial to understanding and documenting materials used in biopharmaceutical production. Dr. Debbie Letham from Charles River discusses in GEN.
Researchers are teaching mice to nose-poke a touchscreen by doling out strawberry milkshakes as part of cognitive testing, a technique they hope will help in the development in translational therapies for diseases like Alzheimer’s. Maksym Kopanitsa, Head of Translational Biology, discusses the concept in Science.
It is a commonly encountered view from the quantitative bioanalysis community that high resolution mass spectrometry (HRMS) is a qualitative technique employed by biotransformation chemists working in “the other” mass spectrometry laboratory. Read more from Iain Love of Charles River in BioAnalysis Zone.
Despite great progress, most newly developed anticancer agents fail clinical trials, mainly due to the use of inappropriate preclinical models. In this context, patient-derived-xenograft (PDX) models has regained interest over the last decade. Vincent Vuaroqueaux, Ph.D. from Charles River discusses in GEN.
Recently, there has been a push in cancer research to establish and characterize large collections of patient-derived tumor xenograft (PDX) models—mice implanted with cancerous tissue from human patients. Learn more from Julia Schueler, DVM, PhD, and Head of In Vivo Operations at Charles River.